Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response...

Related Keywords

Australia ,Brisbane ,Queensland ,California ,United States ,Canada ,Jeremy Bender ,Sabine Mueller ,Laura Cooper ,Courtney Davies ,Samuel Blackman ,European Commission ,Nasdaq ,Drug Administration ,Pediatric Brain Tumor Foundation ,Oncology Consortium ,Company On Linkedin ,Globenewswire Inc ,Society For Neuro ,Exchange Commission ,Head Of Communications ,Day One Biopharmaceuticals Inc ,One Biopharmaceuticals ,Day One ,California San Francisco Benioff Children ,Response Assessment ,Pediatric Neuro Oncology Low Grade Glioma ,Brain Tumor ,Everyday Support From ,Zone Investors ,Breakthrough Therapy ,Rare Pediatric Disease ,Orphan Drug ,Product Information ,Pediatric Neuro Oncology Consortium ,Neuro Oncology High Grade Glioma ,Neuro Oncology Low Grade Glioma ,Pacific Pediatric Neuro Oncology Consortium ,Private Securities Litigation Reform Act ,Sci Advisors ,